LGALS1 acts as a pro-survival molecule in AML

Area of Science:

• Molecular Biology
• Cancer Research
• Immunology

Background:

• Galectin LGALS1 is a glycan-binding protein involved in cell survival and RAS signaling.
• LGALS1 is crucial in acute lymphoblastic leukemia, but its role in acute myeloid leukemia (AML) is unclear.
• Previous studies showed LGALS1 suppression sensitized AML cell lines to BCL2 inhibitors.

Purpose of the Study:

• To investigate the role of LGALS1 in AML pathogenesis and survival.
• To determine if reducing LGALS1 expression impacts AML progression in vivo.
• To explore the molecular mechanisms underlying LGALS1's function in AML.

Main Methods:

• In vivo murine OCI-AML3 xenograft model with LGALS1 shRNA.
• Gene expression profiling via RNASeq on OCI-AML3 and THP-1 cells (p53 WT and mutant).
• Analysis of LGALS1 mRNA levels in AML patient samples.

Main Results:

• Mice with LGALS1-reduced OCI-AML3 cells exhibited significantly longer survival.
• RNASeq revealed distinct gene expression differences and pathway involvement between cell lines.
• Elevated LGALS1 mRNA in AML patients correlated with shorter disease-free survival and increased bone marrow blasts.

Conclusions:

• LGALS1 plays a significant role in AML, potentially within the tumor microenvironment.
• Reducing LGALS1 expression offers a potential therapeutic strategy for AML patients.
• Targeting LGALS1 may represent a novel approach to improve AML treatment outcomes.